Expert Review of Clinical Pharmacology最新文献_第10页

Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β₂-agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis. 吸入性皮质类固醇加长效β2-受体激动剂固定剂量组合与长效毒蕈碱拮抗剂在支气管扩张症中的有效性和安全性比较。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2306218

Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu

{"title":"Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β2-agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis.","authors":"Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu","doi":"10.1080/17512433.2024.2306218","DOIUrl":"10.1080/17512433.2024.2306218","url":null,"abstract":"Background: This study aimed to evaluate the effectiveness and safety of fixed-dose combination (FDC) inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in bronchiectasis.Research design and methods: A retrospective cohort study analyzed electronic medical records of bronchiectasis patients initiating ICS/LABA FDC or LAMA between 2007 and 2021. All bronchiectasis diagnoses were made by radiologists using high-resolution computed tomography.Results: Of the 1,736 patients, 1,281 took ICS/LABA FDC and 455 LAMA. Among the 694 propensity score matched patients, ICS/LABA FDC had comparable outcomes to LAMA, with HRs of 1.22 (95% CI 0.81-1.83) for hospitalized respiratory infection, 1.06 (95% CI 0.84-1.33) for acute exacerbation, and 1.06 (95% CI 0.66-1.02) for all-cause hospitalization. Beclomethasone/formoterol (BEC/FOR) or budesonide/formoterol (BUD/FOR) led to a lower risk of acute exacerbation compared to fluticasone/salmeterol (FLU/SAL) (BEC/FOR HR 0.59, 95% CI 0.43-0.81; BUD/FOR HR 0.68, 95% CI 0.50-0.93). BEC/FOR resulted in lower risks of hospitalized respiratory infection (HR 0.48, 95% 0.26-0.86) and all-cause hospitalization (HR 0.55, 95% 0.37-0.80) compared to FLU/SAL.Conclusion: Our findings provide important evidence on the effectiveness and safety of ICS/LABA FDC compared with LAMA for bronchiectasis. BEC/FOR and BUD/FOR were associated with better outcomes than FLU/SAL.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022. 二甲双胍不良事件概况：基于 2004 年至 2022 年 FDA 不良事件报告系统 (FAERS) 的药物警戒研究。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2306223

Yikuan Du, Jinfeng Zhu, Zhuoming Guo, Zhenjie Wang, Yuni Wang, Mianda Hu, Lingzhi Zhang, Yurong Yang, Jinjin Wang, Yixing Huang, Peiying Huang, Mianhai Chen, Bo Chen, Chun Yang

{"title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.","authors":"Yikuan Du, Jinfeng Zhu, Zhuoming Guo, Zhenjie Wang, Yuni Wang, Mianda Hu, Lingzhi Zhang, Yurong Yang, Jinjin Wang, Yixing Huang, Peiying Huang, Mianhai Chen, Bo Chen, Chun Yang","doi":"10.1080/17512433.2024.2306223","DOIUrl":"10.1080/17512433.2024.2306223","url":null,"abstract":"Background: Metformin has the potential for treating numerous diseases, but there are still many unrecognized and unreported adverse events (AEs).Methods: We selected data from the United States FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2022 for disproportionality analysis to assess the association between metformin and related adverse events.Results: In this study 10,500,295 case reports were collected from the FAERS database, of which 56,674 adverse events related to metformin were reported. A total of 643 preferred terms (PTs) and 27 system organ classes (SOCs) that were significant disproportionality conforming to the four algorithms simultaneously were included. The SOCs included metabolic and nutritional disorders (p = 0.00E + 00), gastrointestinal disorders (p = 0.00E + 00) and others. PT levels were screened for adverse drug reaction (ADR) signals such as acute pancreatitis (p = 0.00E + 00), melas syndrome, pemphigoid (p = 0.00E + 00), skin eruption (p = 0.00E + 00) and drug exposure during pregnancy (p = 0.00E + 00).Conclusion: Most of our results were consistent with the specification, but some new signals of adverse reactions such as acute pancreatitis were not included. Therefore, further studies are needed to validate unlabeled adverse reactions and provide important support for clinical monitoring and risk identification of metformin.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study. 基于人工智能的青少年舍曲林剂量预测模型：一项真实世界研究。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2304009

Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu

{"title":"Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study.","authors":"Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu","doi":"10.1080/17512433.2024.2304009","DOIUrl":"10.1080/17512433.2024.2304009","url":null,"abstract":"Background: Variability exists in sertraline pharmacokinetic parameters in individuals, especially obvious in adolescents. We aimed to establish an individualized dosing model of sertraline for adolescents with depression based on artificial intelligence (AI) techniques.Methods: Data were collected from 258 adolescent patients treated at the First Hospital of Hebei Medical University between December 2019 to July 2022. Nine different algorithms were used for modeling to compare the prediction abilities on sertraline daily dose, including XGBoost, LGBM, CatBoost, GBDT, SVM, ANN, TabNet, KNN, and DT. Performance of four dose subgroups (50 mg, 100 mg, 150 mg, and 200 mg) were analyzed.Results: CatBoost was chosen to establish the individualized medication model with the best performance. Six important variables were found to be correlated with sertraline dose, including plasma concentration, PLT, MPV, GL, A/G, and LDH. The ROC curve and confusion matrix exhibited the good prediction performance of CatBoost model in four dose subgroups (the AUC of 50 mg, 100 mg, 150 mg, and 200 mg were 0.93, 0.81, 0.93, and 0.93, respectively).Conclusion: The AI-based dose prediction model of sertraline in adolescents with depression had a good prediction ability, which provides guidance for clinicians to propose the optimal medication regimen.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into the population pharmacokinetics and pharmacodynamics of quetiapine: a systematic review 洞察喹硫平的群体药代动力学和药效学：系统综述

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-18 DOI: 10.1080/17512433.2023.2295428

Lu Han, Jia-Qin Gu, Jue-Hui Mao, Xiao-Qin Liu, Zheng Jiao

引用次数: 0

Response to letter to the editor: therapeutic importance of proteinuria classification in children with congenital anomalies of the kidney and urinary tract 回复致编辑的信：肾脏和泌尿道先天性异常儿童蛋白尿分类的治疗重要性

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-13 DOI: 10.1080/17512433.2023.2295005

Giulio Rivetti, Pietro Gizzone, Anna Di Sessa, Stefano Guarino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo

引用次数: 0

Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges 在临床试验中实施药物遗传学：关于当前方法、伦理和监管挑战的思考

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-13 DOI: 10.1080/17512433.2023.2293999

Irene García, Enrique Seco-Meseguer, Alberto M Borobia, Antonio J Carcas-Sansuán

引用次数: 0

Letter to the editor: type of proteinuria might be essential for RAAS-I treatment in children with CAKUT 致编辑的信：蛋白尿类型可能是 RAAS-I 治疗 CAKUT 儿童的关键所在

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-12 DOI: 10.1080/17512433.2023.2295004

Alessia Marcellino, Riccardo Lubrano

引用次数: 0

Challenges, unmet needs and future directions – a critical evaluation of the clinical trial landscape in schizophrenia research 挑战、未满足的需求和未来方向--对精神分裂症研究中的临床试验情况进行批判性评估

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-12 DOI: 10.1080/17512433.2023.2293996

Elias Wagner, Jurjen J. Luykx, Wolfgang Strube, Alkomiet Hasan

引用次数: 0

The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses 基于药物靶向孟德尔随机化和真实世界药物警戒分析的 ACE 抑制剂与银屑病之间的关系

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-11 DOI: 10.1080/17512433.2023.2292605

Qiubai Jin, Feihong Ren, Ping Song

引用次数: 0

Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia 与痴呆症患者药物相关住院治疗有关的不良临床结果

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2023-12-11 DOI: 10.1080/17512433.2023.2294007

Anum Saqib Zaidi, Gregory M Peterson, Colin M Curtain, Mohammed S Salahudeen

引用次数: 0